EU Accelerated Assessment Tracker

 
• By Maureen Kenny

GSK secured accelerated assessment for dostarlimab at the European Medicines Agency but there was no such good news for Merck/AstraZeneca's selumetinib. MYR Pharmaceuticals' bulevirtide has reverted to standard review timelines.

More from Europe

More from Geography